Pharmacotherapy and Intensive Treatment - 2

This study has been completed.

First Received: September 20, 1999 Last Updated: March 23, 2009 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Department of Veterans Affairs
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000218

Purpose

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Carbamazepine	Phase IV

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Pharmacotherapy and Intensive Treatment

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Carbamazepine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Severity addiction
Depression
Depression, anxiety

Estimated Enrollment:	353
Study Completion Date:	June 2005

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000218

Locations

United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Department of Veterans Affairs

Investigators

Principal Investigator:

William Haning, M.D.

University of Kansas

More Information

No publications provided

Study ID Numbers:	NIDA-06954-2, R18-06954-2
Study First Received:	September 20, 1999
Last Updated:	March 23, 2009
ClinicalTrials.gov Identifier:	NCT00000218 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Tranquilizing Agents
Disease
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Disorders of Environmental Origin
Antimanic Agents
Pharmacologic Actions
Pathologic Processes

Carbamazepine
Mental Disorders
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Substance-Related Disorders
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on November 27, 2009